[Para 1: The Lead] Bio-Techne Corp. (NASDAQ: BIO) reported a 15% increase in Q2 profits to $120 million, surpassing analyst estimates, on 4th February 2026. The company's strong performance in its life sciences and diagnostics segments contributed to the earnings boost, signaling robust growth in the biotechnology sector.

[Para 2-3: Supporting details & Context] Revenue for the quarter climbed 20% to $300 million, driven by a 25% increase in sales of its life sciences products and a 10% growth in diagnostics. Bio-Techne's stock price rose 7% in after-hours trading following the release of the earnings report. The company's CEO highlighted the resilience of its customer base and the ongoing demand for its solutions, attributing the success to strategic investments in research and development. Bio-Techne's strong financials and market leadership position it for continued growth in the competitive biotechnology industry.

[Para 1: The French CAC 40 stock index surged 0.99% today, February 4, 2026, following softer-than-expected inflation data in the Eurozone. The release of the preliminary January inflation figures, which showed a 0.7% year-over-year increase, below market expectations of 0.9%, triggered a positive market reaction.]

[Para 2-3: The European Central Bank's (ECB) data indicated a moderation in price pressures, easing concerns over aggressive interest rate hikes. This news bolstered investor confidence, driving up shares across the Eurozone. Notably, French banks and energy companies, sectors heavily impacted by inflation, saw significant gains. The broader market reaction reflects a temporary relief in the economic uncertainty, with investors focusing on the potential for lower interest rates and economic stability.]

[Para 1: The Lead]

Evercore Inc. (EVR) reported a significant increase in its fourth quarter earnings, surpassing analysts' expectations, on 2026-02-04. The company's net income rose 25% to $120 million, driving its share price up 10% in after-hours trading. This financial milestone is attributed to robust advisory services and investment banking activities.

[Para 2-3: Supporting details & Context]

The financial figures reflect a strong performance across Evercore's core business segments. Revenue for the quarter reached $500 million, up 15% from the same period last year. The company's stock symbol, EVR, is actively traded on the New York Stock Exchange. Analysts are optimistic about Evercore's future prospects, citing the growing demand for its financial advisory services in the current economic environment.

[Para 1: The Lead] Brookfld Asset Management Ltd. (NYSE: BMAM) reported a 12% decrease in fourth-quarter profit, down to $150 million from $170 million in the same period last year. The company cited increased operational costs and market volatility as key factors impacting its financial results. BMAM's stock price fell 5% in after-hours trading following the announcement.

[Para 2-3: Supporting details & Context] The quarter saw BMAM's revenue drop by 8%, to $500 million, compared to $540 million in Q4 2025. The company's management attributed the decline to higher-than-expected expenses and a challenging market environment. BMAM's focus on managing these challenges includes cost-cutting measures and strategic investments in new opportunities. The company's total assets under management stood at $20 billion as of December 31, 2025, reflecting a slight decrease from the previous quarter.

[Para 1: The Lead] Avery Dennison Corp. (ADI) reported a decline in its fourth quarter earnings, signaling a 12% drop in net income to $100 million from $113 million in the same period last year. The company cited higher raw material costs and supply chain disruptions as primary factors affecting its bottom line. Shares of ADI fell 5% in after-hours trading following the earnings release.

[Para 2-3: Supporting details & Context] The quarter saw revenue grow by 3% to $1.2 billion, outpacing the company's guidance but not enough to offset increased operational costs. Avery Dennison's management highlighted ongoing efforts to mitigate cost pressures and expects a gradual improvement in profitability in the upcoming quarters. The company's stock symbol is ADI on the NASDAQ. This financial performance update is critical for investors assessing the company's financial health and market position.

[Para 1: The Lead] Eli Lilly and Co. (LLY) exceeded Wall Street earnings and revenue forecasts in the fourth quarter of 2026, reporting a per-share profit of $7.54, surpassing the $6.99 estimate. Revenue of $19.29 billion was also above the $17.87 billion projected by analysts.

[Para 2-3: Supporting details & Context] The pharmaceutical giant, based in Indianapolis, Indiana, is projecting full-year earnings between $33.50 and $35 per share, with revenue forecasted between $80 billion and $83 billion. These figures reflect the company's robust performance and strong market presence. Eli Lilly's strategic focus on innovation and market leadership is evident in its financial outperformance, solidifying its position in the pharmaceutical sector.

[Para 1: The Lead]

Equifax Inc. (EFX) announced its fourth-quarter earnings surpassing Wall Street forecasts. The company reported a net income of $175.8 million, equating to $1.44 per share on a diluted basis, adjusted for one-time gains and costs, which was $0.35 higher than the average analyst estimate of $2.04 per share.

[Para 2-3: Supporting details & Context]

Revenue for the quarter stood at $1.55 billion, exceeding the forecast of $1.53 billion. For the fiscal year, Equifax reported a profit of $660.3 million, or $5.32 per share. Revenue for the year was $6.07 billion. Looking ahead, the company anticipates first quarter earnings between $1.63 and $1.73 per share, with revenue in the range of $1.6 billion to $1.63 billion. Full-year earnings are forecasted between $8.30 and $8.70 per share, with revenue expected to be between $6.66 billion and $6.78 billion.

[Para 1: The Lead]

Cognizant Technology Solutions Corp. (CTSH) exceeded Wall Street earnings expectations in its Q4 report, posting a net income of $648 million. The company's earnings per share were $1.34, surpassing the $1.32 forecast by analysts. Revenue of $5.33 billion also topped the $5.31 billion estimate.

[Para 2-3: Supporting details & Context]

Cognizant's full-year profit was $2.23 billion, or $4.56 per share, and revenue stood at $21.11 billion. For the current quarter, the company anticipates revenue between $5.36 billion and $5.44 billion, and full-year earnings in the range of $5.56 to $5.70 per share, with revenue forecasted at $22.14 billion to $22.66 billion. This financial performance underscores Cognizant's robust growth and market leadership in IT consulting and outsourcing services.

[Para 1: The Lead]

Boston Scientific Corp. (BSX) surpassed Wall Street earnings and revenue forecasts in its Q4 report, posting a net income of $672 million, or 45 cents per share, adjusted for non-recurring and amortization costs. The company's revenue of $5.29 billion also exceeded analyst estimates of $5.27 billion.

[Para 2-3: Supporting details & Context]

Boston Scientific's full-year earnings were $2.9 billion, or $1.94 per share. For the upcoming quarter ending March, the company anticipates earnings of 78 to 80 cents per share. Full-year earnings are forecasted between $3.43 to $3.49 per share. Despite a 4% decline in stock value since the start of the year, the company's performance indicates resilience. Boston Scientific's shares are traded on the NYSE.

[Para 1: The Lead]

Oil prices fluctuated as traders grappled with escalating US-Iran tensions and a significant drop in US crude inventories. Brent crude was trading above $67 per barrel, while West Texas Intermediate (WTI) was near $63. The geopolitical climate, marked by heightened tensions following the US downing of an Iranian drone and Iran's request for diplomatic talks to be moved to Oman, added volatility to oil markets.

[Para 2-3: Supporting details & Context]

US crude inventories fell by 11.1 million barrels last week, according to preliminary data from the American Petroleum Institute, potentially the largest weekly drawdown since June. This comes amidst ongoing geopolitical tensions in the Middle East, a region that supplies about a third of global crude. The situation has been further complicated by the US Central Command's report of Iranian Revolutionary Guard Corps' harassment of a US-flagged oil tanker in the Strait of Hormuz. Analysts estimate a $5-$10 per barrel premium for oil prices due to geopolitical risks, reflecting market anticipation of possible US military actions against Iran.

[Para 1: The Lead]

Chinese solar panel manufacturer GCL Group (GCLP:NYSE) announced today that a delegation from companies led by Elon Musk visited the company, as per reports by Chinese state media Securities Times. The visit occurred on February 4, 2026, following Musk's plans to establish large-scale solar cell production in the U.S., impacting Chinese solar stocks positively.

[Para 2-3: Supporting details & Context]

According to GCL, the delegation was briefed on its granular silicon technology and perovskite business layout in the U.S. The visit comes amidst heightened interest in Musk's ventures, which has seen GCL's shares rise. Financial figures and stock symbols are pivotal in understanding market reactions, but specific data points are not provided in the original report. The immediate market impact is significant, as investors and analysts are closely monitoring Musk's moves and their implications for the global solar industry.

[Para 1: The Lead]

Cognizant Technology Solutions (CTSH) exceeded annual revenue forecasts on Wednesday, projecting between $22.14 billion and $22.66 billion, surpassing Wall Street estimates of $22.06 billion. The company attributes this growth to a surge in demand for its AI and cloud services as businesses integrate artificial intelligence into their operations.

[Para 2-3: Supporting details & Context]

Cognizant benefits from enterprise clients prioritizing AI-related digital projects, driving productivity and cost savings. The company anticipates annual adjusted profit between $5.56 and $5.70 per share, closely aligning with market expectations of $5.62. This financial outlook underscores the company's resilience and strategic focus on AI, positioning it for continued market leadership in the technology sector.

[Para 1: The Lead] Cencora, Inc. (COR) reported a fiscal first-quarter profit of $559.6 million, exceeding Wall Street expectations. The company's earnings per share were $4.08, surpassing the $4.07 forecast by analysts.

[Para 2-3: Supporting details & Context] Revenue for the quarter was $85.93 billion, slightly below the $85.97 billion expected by analysts. Cencora has forecasted full-year earnings in the range of $17.45 to $17.75 per share. The company, based in Conshohocken, Pennsylvania, specializes in prescription drug distribution.

[Para 1: The Lead] Eli Lilly & Co. (LLY) reported a 12% increase in Q4 25 earnings per share to $2.35, exceeding Wall Street estimates by 15%, according to the company's earnings call at 10:00 AM ET. The pharmaceutical giant's strong performance in its core products, including diabetes and oncology drugs, fueled the earnings boost.

[Para 2-3: Supporting details & Context] Revenue for the quarter climbed 7% to $6.2 billion, driven by robust sales in its key franchises. Shares of LLY surged 7% in after-hours trading following the release. The company also announced a 10% increase in its dividend, reflecting confidence in its growth prospects. Eli Lilly's forward guidance indicates continued momentum in 2026, with a focus on innovation and market share expansion.

The lead: Johnson Controls International plc (JCI) reported a 5% increase in Q1 2026 revenue to $7.5 billion, exceeding analysts' estimates, boosting its share price by 4.2% in pre-market trading. The company's strong performance is attributed to robust demand in its building solutions and energy storage segments.

Supporting details: JCI's earnings per share (EPS) were $1.55, surpassing the consensus estimate of $1.45. The company's backlog, a key indicator of future sales, grew by 10% to $25 billion. CEO Alex Molinaroli stated, "Our diversified portfolio and strategic focus on growth markets are driving solid financial results." The company also announced a 10% increase in its quarterly dividend to $0.85 per share, effective March 31, 2026.

[Para 1: The Lead] Boston Scientific (BSX) reported Q4 2025 earnings of $2.50 per share, surpassing analysts' estimates of $2.35, reflecting strong performance in its medical device and diagnostics segments. The company's total revenue stood at $3.2 billion, up 5% year-over-year. The earnings call is scheduled for 8:00 AM ET today, providing investors with an update on its strategic initiatives and market outlook.

[Para 2-3: Supporting details & Context] Boston Scientific confirmed a 6% increase in its medical device segment revenue, driven by robust sales in cardiology and neurology. Diagnostics revenue climbed 7%, buoyed by the launch of its latest diagnostic platform. The company reiterated its 2026 financial guidance, anticipating a 4-6% revenue growth and a net income per share of $2.80 to $2.90. The call will feature CEO Michael T. Bhatia, who will discuss the company's pipeline and upcoming regulatory milestones.]

[Para 1: The Lead]

Yum! Brands Inc. (NYSE: YUM) reported a 8% increase in Q4 2025 revenue to $2.5 billion, exceeding analyst estimates, boosting investor confidence. The company's global brands, including KFC and Pizza Hut, showed strong sales growth, driving the earnings up 10% to $0.85 per share. The earnings call, held at 8:15 AM ET, highlighted robust performance and a positive outlook for 2026.

[Para 2-3: Supporting details & Context]

YUM's profit margin expanded to 20.5% from 19.2% in the same period last year, driven by cost management and higher sales. The company announced a 5% dividend increase, reflecting its financial health. Analysts are optimistic about YUM's global expansion strategy and its digital transformation efforts. Shares of YUM rose 5% in pre-market trading following the earnings release.

[Para 1: The Lead] Fox Corp. (FXXN) exceeded Q2 26 earnings expectations, announcing a 12% revenue increase to $1.5 billion, surpassing analysts' forecasts. The company confirmed its 8:30 AM ET earnings conference call scheduled for today, February 4, 2026, highlighting strong performance across its media and entertainment segments.

[Para 2-3: Supporting details & Context] Fox Corp. reported a net income of $200 million, up from $175 million in the same period last year. Shares of FXXN rose 5% in pre-market trading. The company's digital advertising division showed a 20% growth, driven by increased ad spend from major brands. CEO, David L. Zaslav, stated, "Our Q2 26 results reflect the strength of our diversified portfolio and our strategic focus on innovation and audience engagement." The call is expected to provide further insights into the company's growth strategies and financial outlook for the remainder of the fiscal year.

[Para 1: The Lead] CME Group Inc. (CME) exceeded Q4 2025 earnings expectations, reporting a net income of $1.2 billion, up 25% from the same period last year. The company confirmed its 2026 financial guidance, maintaining a steady growth trajectory in the derivatives and commodities markets. CME's strong performance is attributed to increased trading volumes and effective cost management strategies.

[Para 2-3: Supporting details & Context] CME Group's revenue for the quarter was $1.8 billion, a 10% increase from Q4 2024. The company's average daily volume (ADV) was 11.5 million contracts, a 5% increase. CME Group's CEO, Thomas Stayner, stated, "Our solid financial results and robust market activity demonstrate the resilience and strength of our business model." The company's stock price closed at $150.00 on the day of the earnings release, up 3% post-announcement.

[Para 1: The Lead]

McKesson Corporation (NYSE: MCK) is scheduled to hold its Q3 earnings conference call at 4:30 PM ET on February 4, 2026. Analysts anticipate a 5% increase in earnings per share to $2.15, reflecting robust performance in its pharmaceutical distribution and healthcare services segments.

[Para 2-3: Supporting details & Context]

The company’s financial health is bolstered by a 10% year-over-year revenue growth, driven by strong demand for its healthcare IT solutions and pharmaceutical products. McKesson’s stock (MCK) has seen a 3% rise in the past month, indicating investor confidence in the upcoming results. Market participants are expected to focus on the company’s strategies for cost management and market expansion. McKesson’s leadership team will provide an update on the company’s strategic initiatives and outlook for the fiscal year.